Kivara Neurosciences

What If We Could Detect Alzheimer's Before Symptoms Begin?

Kivara Neurosciences is developing next-generation molecular diagnostics designed to identify the earliest biological signals associated with neurodegenerative disease — creating new opportunities for prevention, intervention, and precision medicine.

Explore NeuroIntercept™The Science
Glowing neural network visualization
Neural Signal · Live
Mapping the silent decades.

The Growing Neurodegenerative Disease Crisis

Neurodegenerative diseases are among the fastest-growing health challenges of the 21st century. As populations age, millions of individuals and families are being impacted by Alzheimer's disease, dementia, Parkinson's disease, and related disorders. The need for earlier detection has never been greater.

Three generations of a family sitting together in warm window light, holding hands
Behind every statistic
A family. A future. A reason.
0.0M
Americans

Living with Alzheimer's dementia today

Projections suggest that number could approach 13.8 million by 2060 without major breakthroughs.

0M+
New cases per year by 2060

Dementia cases expected to double

Researchers project approximately 1 million new dementia cases per year in the United States by 2060.

0.0M
Americans

Living with Parkinson's disease

The second most common neurodegenerative disorder after Alzheimer's disease.

0M+
People worldwide

Living with dementia globally

Projections reach 139 million by 2050 as populations continue to age.

The Trajectory

The Burden Is Accelerating

Without significant advances in prevention, detection, and treatment, the number of Americans living with Alzheimer's disease is expected to nearly double over the coming decades.

2020
5.8M
2060 (proj.)
13.8M
U.S. Alzheimer's Dementia
Projected prevalence, 2020–2060 (millions)
0M3M6M9M12M15M20202030204020502060
Year Range
2020 → 2060+138%
Projected prevalence
Growth area
5-year data point
The Hidden Biology

Disease begins long before symptoms appear

  1. 01Pre-clinical
    Today
    Protein Changes Begin
  2. 02Pre-clinical
    Years 1–5
    Neuroinflammation Develops
  3. 03Pre-clinical
    Years 5–10
    Neuronal Injury Occurs
  4. 04Symptomatic
    Years 10+
    Cognitive Symptoms Appear
  5. 05Clinical
    Diagnosis
    Clinical Diagnosis
  6. 06Clinical
    After
    Disease Progression

By the time memory loss and cognitive symptoms appear, disease-related biological changes may have been developing for years. Early detection offers the opportunity to identify disease-associated biological signals before significant neurological decline occurs.

Modern molecular biology laboratory with scientists analyzing genomic and neural network data
Inside the Lab
Decoding the molecular signals that precede disease.
Why Earlier Detection Matters

Earlier signals create earlier options

Earlier Intervention

Potentially identify at-risk individuals sooner, opening a window for clinical action.

Better Clinical Decisions

Enable more informed monitoring, stratification, and treatment planning.

Improved Research

Support enrollment into clinical studies earlier in disease progression.

Better Patient Outcomes

Create opportunities to act before extensive neurological damage occurs.

Why Kivara Exists

Building the future of neurodegenerative disease detection

Kivara Neurosciences is developing advanced molecular diagnostics designed to identify biological signals associated with neurodegenerative disease risk and progression. Leveraging the InterceptIQ™ platform, Kivara combines multi-omic biomarkers, artificial intelligence, and precision diagnostics to support earlier detection and more informed clinical decision-making.

Explore NeuroIntercept™The Science
  • Multi-omic biomarkers
  • Artificial intelligence
  • Precision diagnostics
  • InterceptIQ™ platform
The Problem

The Disease Starts Long Before The Symptoms

Biological changes occur silently in the brain for years — and often decades — before memory loss, cognitive impairment, or clinical diagnosis.

Brain scan with highlighted neural pathways
  1. 10–20+ Years Before Diagnosis

    Early Biological Changes

    Silent molecular shifts begin at the cellular level.

  2. Sub-Clinical

    Protein Misfolding

    Misfolded proteins begin to aggregate within neural tissues.

  3. Sub-Clinical

    Cellular Stress

    Inflammatory responses accumulate, signalling distress.

  4. Sub-Clinical

    Neurodegeneration

    Synaptic loss and structural brain changes accelerate.

  5. Symptomatic

    Cognitive Decline

    Memory and cognitive symptoms first become apparent.

  6. Year 0

    Clinical Diagnosis

    Disease is identified — often after irreversible damage.

Current medicine often enters the picture after substantial neurological damage has already occurred.

Scientist holding a vial of blood in a clean lab
The Opportunity

A Window For Earlier Intervention

The ability to identify disease biology before symptoms emerge may create opportunities for a new generation of clinical care.

  • 01Earlier detection
  • 02Patient stratification
  • 03Clinical trial enrollment
  • 04Therapeutic monitoring
  • 05Precision medicine
  • 06Future disease prevention
The Science

Built Upon The InterceptIQ™ Platform

Kivara Neurosciences is leveraging the InterceptIQ™ Disease Interception Platform to develop novel molecular diagnostics for neurodegenerative disease.

Glowing DNA double helix
01
Liquid Biopsy
Minimally invasive blood sample
02
Cell-Free DNA
Circulating molecular fragments
03
Epigenetics
Regulatory signatures of disease
04
Biomarker Discovery
Disease-specific signal isolation
05
Artificial Intelligence
Pattern recognition at scale
06
Molecular Intelligence
Clinically actionable insight
1Sample
2Molecular Analysis
3AI Processing
4Clinical Intelligence
Flagship Program

NeuroIntercept™

A molecular intelligence program focused on identifying biological signals associated with Alzheimer's disease and other neurodegenerative disorders before irreversible neurological damage occurs.

01

Identify disease biology earlier.

Detect molecular signals years before clinical symptoms.

02

Enable intervention sooner.

Create a clinical window for therapeutic action when it matters.

03

Improve long-term outcomes.

Shift the trajectory of neurodegenerative disease.

Pipeline

NeuroIntercept™ Programs

Expanding earlier detection across the neurodegenerative disease landscape.

KIV-ADValidation

NeuroIntercept™ AD

Alzheimer's Disease

KIV-PDDiscovery

NeuroIntercept™ PD

Parkinson's Disease

KIV-MSPre-Clinical

NeuroIntercept™ MS

Multiple Sclerosis

KIV-FXPlanning

Future Programs

Additional Disorders

Vision

The Future Of Neurodegenerative Disease Begins With Earlier Detection

By combining molecular biology, liquid biopsy technologies, biomarker discovery, and artificial intelligence, we aim to create a new paradigm for understanding, monitoring, and ultimately preventing neurological disease.

Clarity For What Matters